FGF2 and breast cancer: For example, miR-205, an FGF2- and VEGFA-targeting molecule that negatively regulates their expression, is highly expressed in breast cancer sensitive to TAC (taxol, doxorubicin, cyclophosphamide) chemotherapy, in contrast to drug-resistance cell lines, in which miR-205 is downregulated [223].